Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics
IKT Price/Volume Stats
| Current price | $2.05 | 52-week high | $4.35 |
| Prev. close | $2.10 | 52-week low | $0.79 |
| Day low | $2.02 | Volume | 51,783 |
| Day high | $2.13 | Avg. volume | 125,167 |
| 50-day MA | $2.25 | Dividend yield | N/A |
| 200-day MA | $1.83 | Market Cap | 13.28M |
IKT Stock Price Chart Interactive Chart >
Inhibikase Therapeutics Inc. (IKT) Company Bio
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Latest IKT News From Around the Web
Below are the latest news stories about INHIBIKASE THERAPEUTICS INC that investors may wish to consider to help them evaluate IKT as an investment opportunity.
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsBOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: What a ride it has been in 2023. The year began with a quick r |
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate completed with minimal adverse events - BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, P |
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityCompany to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ETBOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30, |
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's |
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S. |
IKT Price Returns
| 1-mo | 0.00% |
| 3-mo | 19.22% |
| 6-mo | 122.85% |
| 1-year | -43.99% |
| 3-year | -93.21% |
| 5-year | N/A |
| YTD | 61.42% |
| 2023 | -57.67% |
| 2022 | -65.99% |
| 2021 | -78.70% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...